These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 16280250

  • 1. Long-term efficacy of levetiracetam for partial seizures.
    Abou-Khalil B, Schaich L.
    Seizure; 2005 Dec; 14(8):577-85. PubMed ID: 16280250
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ.
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [Abstract] [Full Text] [Related]

  • 3. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, Weber AM, Stroink H, Geerts Y, Geerts AT, Brouwer OF.
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [Abstract] [Full Text] [Related]

  • 4. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
    Steinhoff BJ, Somerville ER, Van Paesschen W, Ryvlin P, Schelstraete I.
    Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
    [Abstract] [Full Text] [Related]

  • 5. Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy.
    Specchio LM, Boero G, Specchio N, De Agazio G, De Palo A, de Tommaso M, Beghi E, La Neve A.
    Seizure; 2006 Mar; 15(2):112-6. PubMed ID: 16406697
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients.
    Heo K, Lee BI, Yi SD, Huh K, Kim JM, Lee SA, Shin DJ, Song HK, Lee SK, Kim JY, Lu S, Dubois C, Tonner F.
    Seizure; 2007 Jul; 16(5):402-9. PubMed ID: 17369059
    [Abstract] [Full Text] [Related]

  • 7. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials.
    Uthman BM, Almas M, Emir B, Giordano S, Leon T.
    Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392
    [Abstract] [Full Text] [Related]

  • 8. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
    Piña-Garza JE, Nordli DR, Rating D, Yang H, Schiemann-Delgado J, Duncan B, Levetiracetam N01009 Study Group.
    Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
    [Abstract] [Full Text] [Related]

  • 9. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
    Steinhoff BJ, Trinka E, Wieser HG, DACH-LEV Study Group.
    Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.
    Chung S, Ceja H, Gawłowicz J, Avakyan G, McShea C, Schiemann J, Lu S.
    Epilepsy Res; 2012 Aug; 101(1-2):92-102. PubMed ID: 22516508
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
    Xiao Z, Li JM, Wang XF, Xiao F, Xi ZQ, Lv Y, Sun HB.
    Eur Neurol; 2009 Aug; 61(4):233-9. PubMed ID: 19176965
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adjunctive therapy of uncontrolled partial seizures with levetiracetam in Australian patients.
    Somerville ER, McLaughlin DB, Robinson MK, Berkovic SF.
    Epilepsy Behav; 2007 Nov; 11(3):338-42. PubMed ID: 17851135
    [Abstract] [Full Text] [Related]

  • 16. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B, Hemdal P, Privitera MD.
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
    Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, Shields WD.
    Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
    [Abstract] [Full Text] [Related]

  • 18. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY, Hong Z, Wu X, Wu LW, Wang XF, Zhou D, Zhao ZX, Lv CZ.
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
    Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P.
    Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.